IASLC TTLC 2024 | Non-TKI-based treatment options for EGFR-mutant lung cancer

Timothy Burns, MD, PhD, University of Pittsburgh & UPMC Hillman Cancer Center, Pittsburgh, PA, provides an overview of management strategies for patients with EGFR-mutant lung cancer that do not involve tyrosine kinase inhibitors (TKIs). Amivantamab, an EGFR-MET bispecific antibody, and lazertinib, a third-generation EGFR TKI, have been proven to be beneficial in the Phase III MARIPOSA (NCT04487080) and MARIPOSA-2 (NCT04988295) trials, where there were assessed against osimertinib and chemotherapy alone respectively. Findings from the HERTHENA-Lung01 (NCT04619004) and TROPION-Lung05 (NCT04484142) of patritumab deruxtecan and datopotamab deruxtecan were additionally discussed. This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.